Provectus director granted Series D-1 preferred
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PROVECTUS BIOPHARMACEUTICALS, INC. director John Lacey III reported receiving a grant of 48,917 shares of Series D-1 Convertible Preferred Stock on June 30, 2026. The shares were awarded at a price of $0.00 per share as a compensation-related acquisition.
Each Series D-1 share is convertible into 10 shares of common stock, representing 489,170 underlying common shares for this grant. After this award, Lacey holds 228,509 shares of Series D-1 Convertible Preferred Stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series D-1 Convertible Preferred Stock | 48,917 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- F2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
Key Figures
Key Terms
Series D-1 Convertible Preferred Stock financial
convertible financial
Certificate of Designation regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PVCT director John Lacey III report?
What are John Lacey III’s Series D-1 Preferred holdings in PVCT after this Form 4?
When will PVCT’s Series D-1 Convertible Preferred Stock automatically convert?
Was the PVCT insider transaction a market purchase or a compensation grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.